Senores Pharmaceuticals (NSE:SENORES) ROE % Adjusted to Book Value: 3.61% (As of Mar. 2026)


NSE:SENORES Senores Pharmaceuticals Ltd NSE:SENORES
29 GF Score
Price ₹1,358.80
! 7 Warning Signs
View Full Analysis

What is Senores Pharmaceuticals ROE % Adjusted to Book Value?

Senores Pharmaceuticals NSE:SENORES -0.44% 29 ROE % Adjusted to Book Value is 3.61% as of Mar. 2026. GuruFocus rates NSE:SENORES with a GF Score™ of 29/100. The stock has 7 warning signs investors should review.

Senores Pharmaceuticals's ROE % for the quarter that ended in Mar. 2026 was 13.54%. Senores Pharmaceuticals's PB Ratio for the quarter that ended in Mar. 2026 was 3.75. Senores Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 3.61%.

Senores Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Senores Pharmaceuticals ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Senores Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Senores Pharmaceuticals ROE % Adjusted to Book Value Chart

Senores Pharmaceuticals Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
ROE % Adjusted to Book Value
0.00 0.00 0.00 3.54 3.58

Senores Pharmaceuticals Quarterly Data
Mar22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.72 0.00 4.09 0.00 3.61

NSE:SENORES vs LLY, JNJ, ABBV: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - General subindustry, Senores Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Senores Pharmaceuticals ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Senores Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Senores Pharmaceuticals's ROE % Adjusted to Book Value falls into.


NSE:SENORES
29GF Score
Senores Pharmaceuticals Ltd NSE:SENORES
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Senores Pharmaceuticals ROE % Adjusted to Book Value Calculation

Senores Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=13.42% / 3.75
=3.58%

Senores Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=13.54% / 3.75
=3.61%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 3.61% mean?
Senores Pharmaceuticals (NSE:SENORES) has a ROE % Adjusted to Book Value of 3.61% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Senores Pharmaceuticals and its competitors.
Is Senores Pharmaceuticals' ROE % Adjusted to Book Value too high?
Senores Pharmaceuticals' current ROE % Adjusted to Book Value is 3.61%. Overall, Senores Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Senores Pharmaceuticals' ROE % Adjusted to Book Value compare to LLY and JNJ?
Senores Pharmaceuticals' ROE % Adjusted to Book Value of 3.61% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Senores Pharmaceuticals and its competitors. Senores Pharmaceuticals's current ROE % Adjusted to Book Value is 3.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senores Pharmaceuticals stock overvalued right now?
Senores Pharmaceuticals (NSE:SENORES) has a current ROE % Adjusted to Book Value of 3.61%. The current ROE % Adjusted to Book Value is 3.61%. Senores Pharmaceuticals' overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Senores Pharmaceuticals (NSE:SENORES), the current ROE % Adjusted to Book Value is 3.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Senores Pharmaceuticals Business Description

Other Exchanges 544319:India
Address Ambali Bopal Road, 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ahmedabad, GJ, IND, 380054
Senores Pharmaceuticals Ltd is a research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of the USA, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing the company as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, It strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.
29GF Score

Get the complete analysis for NSE:SENORES

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,358.80
Price